After just one year on the job, Vikram Bajaj has left his post as chief scientific officer of cancer biotech GRAIL and is joining investment firm Foresite Capital as managing director.
San Francisco-based Foresite, a VC and private equity firm with $1.2 billion in assets under management, will leverage Bajaj’s background in genetics and data science to find investment opportunities in personalized medicine. Jim Tananbaum, Foresite’s CEO, told Axios that hiring Bajaj is about expanding the firm’s areas of expertise. He thinks personalized medicine is a safe bet.
